Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Tarsus Pharmaceuticals, Inc. Director's Dealing 2021

Jun 18, 2021

31511_dirs_2021-06-17_67c79a3f-c29d-4157-a28f-15c59b1f12d6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2021-06-15

Reporting Person: Ackermann Michael (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-15 Common Stock A 4257 $0.00 Acquired 1233181 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-15 Stock Option (right to buy) $35.26 A 10000 Acquired 2031-06-15 Common Stock (10000) Direct
2021-06-15 Stock Option (right to buy) $35.26 A 10000 Acquired 2031-06-15 Common Stock (10000) Direct
2021-06-15 Restricted Stock Units $ A 4257 Acquired Common Stock (4257) Direct

Footnotes

F1: The Reporting Person was granted restricted stock units ("RSUs") in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The RSUs are fully vested as of the date of grant.

F2: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3: Option granted in connection with the Reporting Person's service as a non-employee director as of the closing of the Company's initial public offering and continued service as of the Company's 2021 annual meeting of stockholders. The option is fully vested.

F4: Each RSU represents a contingent right to receive one share of the Company's common stock.

F5: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2021 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.